Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904670 · ClinicalTrials.gov registry record · Phase 3
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT00904670 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 45 participants.
The verdict
NCT00904670, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages 6-12 years with ADHD.
Interventions
- DRUG Placebo
- DRUG Quillivant Oral Suspension XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904670
The ClinicalTrials.gov registry entry for NCT00904670 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00904670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904670 about?
NCT00904670 is a clinical study titled "Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)". The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages 6-12 years with ADHD.
What is the current status of trial NCT00904670?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2009-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00904670?
The interventions under investigation include: Placebo (DRUG), Quillivant Oral Suspension XR (DRUG).
Who is sponsoring clinical trial NCT00904670?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.